Why Genes Matter

We're in the midst of a revolution in how prostate cancer is treated — and it's being led by new knowledge about the genes behind the disease.


Progress Report: Tarek Bismar, MD

Investigator: Tarek Bismar, MD – Associate Professor, University of Calgary Combined role of TMPRSS2-ERG gene fusion and PTEN genomic deletions in prostate cancer progression The two most common genomic aberrations in prostate cancer are the ERG gene rearrangements and PTEN deletion. TMPRSS2-ERG represents the most common form of ERG rearrangements..


Progress Report: Barbara Graves, Ph.D; Peter Hollenhorst, Ph.D

Co-Investigator: Barbara Graves, PhD –Professor and Chair, Oncological Sciences, Senior Director for Lab Research, Huntsman Cancer Institute, University of Utah Co-Investigator: Peter Hollenhorst, PhD –Assistant Professor, Biochemistry and Molecular Biology, School of Medicine, Indiana University ETS Protein Targets in Prostate Cancer—Understanding Gene Activity that Likely Causes Up to 60 Percent.